Evidence map›Paper›PMID 35123452›Full record

ArticleBMC complementary medicine and therapies2022

Exploring the total flavones of Abelmoschus manihot against IAV-induced lung inflammation by network pharmacology.

Yanan Gao, Zihao Liang, Nianyin Lv, Jinjun Shan, Huihui Zhou, Junfeng Zhang, Liyun Shi

Open access · goldAbstract read
In one paragraph

Article in BMC complementary medicine and therapies, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Therapeutic potential ofFrontiers in pharmacology · 2025
    Review
  6. Article
  7. Natural Modulators of Key Signaling Pathways in Skin Inflammageing.Clinical, cosmetic and investigational dermatology · 2024
    Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Yanan Gao *School of Medicine, Nanjing University of Chinese Medicine, Nanjing, 210046, China.
Zihao Liang *School of Medicine, Nanjing University of Chinese Medicine, Nanjing, 210046, China.
Nianyin LvSchool of Medicine, Nanjing University of Chinese Medicine, Nanjing, 210046, China.
Jinjun ShanThe First School of Clinical Medicine, The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, 210029, China.
Huihui ZhouSchool of Medicine, Nanjing University of Chinese Medicine, Nanjing, 210046, China.
Junfeng ZhangSchool of Medicine, Nanjing University of Chinese Medicine, Nanjing, 210046, China.
Liyun ShiSchool of Medicine, Nanjing University of Chinese Medicine, Nanjing, 210046, China. shi_liyun@njucm.edu.cn.
Nanjing University of Chinese Medicine · CNZhejiang Shuren University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAbelmoschus manihot (L.) Medicus (AM) is a medicinal plant with various biological activities, including anti-inflammatory, antioxidant, antiviral and immunomodulatory. Previous studies have identified total flavones as the primary bioactive ingredient of AM (termed TFA). However, its role and mechanism in counteracting Influenza A virus (IAV) infection are yet to be explored. Therefore, the study aims to study the antiviral and anti-inflammatory effects of TFA on IAV in vitro and in vivo.

methodsA network pharmacology-based approach was applied to identify the antiviral mechanism of TFA against IAV. For the mechanism validation, the cytopathic effect reduction assay evaluated the antiviral activity of TFA in vitro. Meanwhile, the mice were intranasally infected with IAV to induce lung infection. The antiviral effect of TFA was observed in vivo. Further investigation whether the reprogramming microbiome in the TFA treatment group affected antiviral, we conducted a microbial-transfer study with co-housing experiments.

resultsBy applying the network pharmacology-based methods (PPI, GO, and KEGG), we identified 167 potential targets of TFA action, among which 62 targets were related to IAV pathogenesis. A core network containing the pro-inflammatory TNFα, IL-6, IL-1β, MAPKs, and RIG-I receptor signaling pathway was further confirmed as the crucial targets for anti-influenza efficacy of TFA. We demonstrate that TFA provided profound protection against pulmonary IAV infection, which alleviated inflammatory responses, decreased MAPK signaling pathway and expedited viral eradiation.

conclusionsOur study unveils a pivotal role for TFA in controlling viral infection and dampening pathology, making it a promising strategy for treating IAV-induced pneumonia.

Indexed as

AbelmoschusFlavonesInfluenza A virusPneumoniaAnimalsMiceNetwork PharmacologyFlavonesAnti-inflammationAnti-virusIAVNetwork pharmacologyTFA

Identifiers

PMID35123452
PMCPMC8817495
OpenAlexW4210462755

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.